IRONWOOD PHARMACEUTICALS, INC. Cash and Cash Equivalents, Period Increase (Decrease)
IRONWOOD PHARMACEUTICALS, INC. (IRWD) reported Cash and Cash Equivalents, Period Increase (Decrease) of $71.73 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-02-22.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2018-02-22
- IRONWOOD PHARMACEUTICALS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-12-31 was -$36.90M.
- IRONWOOD PHARMACEUTICALS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-09-30 was -$19.49M.
- IRONWOOD PHARMACEUTICALS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2016-12-31 was -$128.93M.
- IRONWOOD PHARMACEUTICALS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2016-09-30 was -$94.39M.
- IRONWOOD PHARMACEUTICALS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2017 was $71.73M.
- IRONWOOD PHARMACEUTICALS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2016 was -$207.28M, a 210.85% decline from fiscal 2015.
- IRONWOOD PHARMACEUTICALS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2015 was $186.99M.
- IRONWOOD PHARMACEUTICALS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2011 was $42.96M.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2017-12-31 | -$36.90M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-22 | -$56.40M derived: sum of 2 quarters · filed 2018-02-22 | $71.73M 10-K · filed 2018-02-22 | |
| 2017-09-30 | -$19.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-02 | $108.64M 10-Q · filed 2017-11-02 | ||
| 2017-06-30 | $128.13M 10-Q · filed 2017-08-03 | |||
| 2016-12-31 | -$128.93M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-22 | -$223.33M derived: sum of 2 quarters · filed 2018-02-22 | -$207.28M 10-K · filed 2018-02-22 | |
| 2016-09-30 | -$94.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-02 | -$78.35M 10-Q · filed 2017-11-02 | ||
| 2016-06-30 | $16.05M 10-Q · filed 2017-08-03 | |||
| 2015-12-31 | $186.99M 10-K · filed 2018-02-22 | |||
| 2011-12-31 | $18.46M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-29 | $39.10M derived: sum of 2 quarters · filed 2012-02-29 | $42.96M 10-K · filed 2012-02-29 | |
| 2011-09-30 | $20.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-09 | $24.50M 10-Q · filed 2011-11-09 | ||
| 2011-06-30 | $3.86M 10-Q · filed 2011-08-12 | |||
| 2010-12-31 | -$14.38M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-29 | $8.96M derived: sum of 2 quarters · filed 2012-02-29 | -$77.98M 10-K · filed 2012-02-29 | |
| 2010-09-30 | $23.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-09 | -$63.61M 10-Q · filed 2011-11-09 | ||
| 2010-06-30 | -$86.95M 10-Q · filed 2011-08-12 | |||
| 2009-12-31 | $55.98M 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |